112
Participants
Start Date
December 23, 2016
Primary Completion Date
July 31, 2022
Study Completion Date
April 7, 2023
RC48-ADC 1.5 mg/kg (HER2 Positive)
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 1.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
RC48-ADC 2.0 mg/kg (HER2 Positive)
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.0mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
RC48-ADC 2.5 mg/kg (HER2 Positive)
15 advanced breast cancer participants with HER2 Positive will be treated with RC48-ADC at a dose of 2.5 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
RC48-ADC 2.0 mg/kg (HER2 Low Expression)
45 advanced breast cancer participants with HER2 Low Expression will be treated with RC48-ADC at a dose of 2.0 mg/kg, every 2 weeks. They will continue the medication until one of the following conditions occurred: disease progression, intolerance of toxicity, withdrawal of informed consent, or treatment for 1 year.
Cancer Hospital Chinese Academy of Medical Sciences, Beijing
The first bethune hospital of jilin unversity, Changchun
Liaoning cancer hospital & institute, Shenyang
Zhejiang cancer hospital, Hangzhou
Affiliated cancer hospital of Harbin medical university, Harbin
The fourth hospital of Hebei medical university, Hebei
Jiangsu Cancer Hospital, Nanjing
RemeGen Co., Ltd.
INDUSTRY